Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Oct 2 - Oct 7
Patient-specific factors that influence choice include: Concurrent diabetes : Patients with type 2 diabetes may have broader access through NHS prescribing pathways BMI and weight loss goals : Higher BMI patients may benefit from agents with greater weight loss efficacy Tolerability : Previous experience with gastrointestinal side effects may guide selection Injection preference : Some patients strongly prefer weekly over daily injections, or oral over injectable formulations Cardiovascular disease : Certain GLP-1 agonists have proven cardiovascular benefits, which may be relevant for high-risk patients Ultimately, the choice should be individualised through shared decision-making between patient and clinician, considering the available evidence, licensed indications, local prescribing policies, and patient preferences
Wegovy has been making the headlines because of its impressive weight loss results
Given these benefits, it is imperative that we continue exploring their broader therapeutic potential beyond glucose lowering. At the studys conclusion, Wu and his team found that study participants taking GLP-1 agonists had a significantly lower cumulative risk of developing dementia namely, 10% with an incidence of about 2.5%
Will buy again.
US$ 26.49
US$ 25.20
US$ 20.79
US$ 26.66
US$ 21.03
US$ 20.55
US$ 21.61
US$ 26.69
US$ 26.32
US$ 22.84
